KEYNOTE-716: Primary melanoma, not lymph nodes, should ‘drive therapeutic decision-making’
Source: Healio, June 2023
Key takeaways:
- Three-year results show durable distant metastasis-free survival and RFS benefits with adjuvant pembrolizumab.
- The regimen should be offered to all patients with stage II disease.
CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.
After more than 3 years of follow-up, patients assigned the anti-PD-1 therapy achieved significantly longer distant metastasis-free survival (DMFS) and RFS, results of the KEYNOTE-716 trial showed.